RecruitingNot ApplicableNCT07395206

Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders

Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders: A Randomized Controlled Pilot Trial


Sponsor

Charite University, Berlin, Germany

Enrollment

60 participants

Start Date

Jan 30, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The Kiso pilot study is a randomized controlled trial to test the acceptability and feasibility of a novel digital intervention, namely the Kiso Mind smartphone app. A parallel-group design is utilized. Participants either receive access to the Kiso Mind intervention and treatment-as-usual (TAU) in the experimental condition or receive treatment as usual (TAU) in the control condition. The intervention is designed for participants diagnosed with either schizophrenia (F20.0) or schizoaffective disorder (F25.0) according to the ICD-10. To examine acceptability, feasibility, and preliminary effectiveness, both self-report and rater-based assessments are administered at baseline (T0) and at the end of the 12-week intervention period (post-intervention T1). Lastly, a qualitative interview will be conducted with participants from the experimental condition. The primary outcome of the present study is the acceptability and feasibility of the Kiso Mind app. The secondary outcome consists of general psychopathology, and positive-, negative-, depressive symptoms, as well as social functioning and self-efficacy ratings.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria4

  • ICD-10: F20 Schizophrenia, F25 Schizoaffective Disorder
  • Age: 18 - 65 years
  • Sufficient German Language Proficiency
  • Ability to Use a Smartphone

Exclusion Criteria7

  • Intensive Psychotherapy Protocols (more than one psychotherapy session a month)
  • CGI-Score \< 3; \> 6
  • No smartphone
  • Neurological Disorders or Brain Damage
  • Acute Suicidality
  • Acute Heavy Substance Abuse or Addiction
  • Current Electroconvulsive Therapy

Interventions

BEHAVIORALDigital: Kiso Mind App

See above.


Locations(1)

Charité - Universitätsmedizin Berlin

Berlin, State of Berlin, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07395206


Related Trials